Benzylamine

Benzylamine

SCHEMBL11763370

Cl.NCCO.NCCO.NCCO.NCc1ccccc1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MPL

The experimentally established mechanism targets of Benzylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 3/20 0.70
TAAR1 Q96RJ0 2/20 0.52
TSHR P16473 2/20 0.50
HTR2A P28223 2/20 0.50
CYP2A6 P11509 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAOB P27338 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ENPP2 Q13822 1/20 0.48
MAOA P21397 1/20 0.44
ABAT P80404 1/20 0.44
F11 P03951 1/20 0.43
PNMT P11086 1/20 0.43
CSNK2A1 P68400 1/20 0.42
KIF11 P52732 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzylamine SCHEMBL28471738 0.90 LOXL2 (0.78) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL28619106 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL30045627 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL27781209 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL9483 0.87
Benzylamine SCHEMBL30098454 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL10942012 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL465924 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL27739746 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6
Benzylamine SCHEMBL15654117 0.87 LOXL2 (0.93) LOXL2TAAR1TSHRHTR2ACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150216985-A1 ENDOSPORE COMPOSITIONS AND USES THEREOF Annuary Healthcare Inc. 2015-08-06 US disclosed
US-20140205546-A1 NANOSCALE PARTICLE FORMULATIONS AND METHODS Annuary Healthcare, Inc. 2014-07-24 US disclosed
US-20140178496-A1 ENDOSPORE COMPOSITIONS AND USES THEREOF Annuary Healthcare Inc. 2014-06-26 US disclosed
US-20130177504-A1 Nanoscale Particle Formulations and Methods Annuary Healthcare, Inc. (US) 2013-07-11 US disclosed
WO-2012174466-A2 NANOSCALE PARTICLE FORMULATIONS AND METHODS Annuary Healthcare, Inc. (US) 2012-12-20 WO disclosed
US-4042368-A Additive for quaternary amine bactericides and algicides, compositions containing same and method of manufacture EPIC CHEMICAL INC. (US) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216985-A1 ENDOSPORE COMPOSITIONS AND USES THEREOF CUTA, SUCLG1, CD47 LOXL2 2631/4885TAAR1 2745/4885TSHR 4575/4885
US-20140178496-A1 ENDOSPORE COMPOSITIONS AND USES THEREOF CUTA, SUCLG1, CD47 LOXL2 2631/4885TAAR1 2745/4885TSHR 4575/4885
US-20140205546-A1 NANOSCALE PARTICLE FORMULATIONS AND METHODS CUTA, S100P, KRT18 LOXL2 1599/4885TAAR1 2200/4885TSHR 4498/4885
US-20130177504-A1 Nanoscale Particle Formulations and Methods CUTA, S100P, KRT18 LOXL2 1599/4885TAAR1 2200/4885TSHR 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.